Baidu
map

nintedanib对恶性胸膜间皮瘤的有效性

2018-05-20 MedSci MedSci原创

近日,欧洲研究人员发现,多靶点小分子抗癌药物nintedanib在临床前模型中显示出对人类恶性胸膜间皮瘤(一种致命的胸部肿瘤)生长的抑制作用

近日,欧洲研究人员发现,多靶点小分子抗癌药物nintedanib临床前模型中显示出对人类恶性胸膜间皮瘤(一种致命的胸部肿瘤)生长的抑制作用。

恶性胸膜间皮瘤(pleural malignant mesothelioma)是发生在胸膜和浆膜表面的具有侵袭性的恶性肿瘤。这一既往认为少见的肿瘤,目前发病率在全球范围内有上升趋势。这可能与相关人群广泛暴露于石棉环境有关,石棉环境是恶性胸膜间皮瘤发病的高危因素。标准的抗间皮瘤治疗包括手术、化疗、放疗或多模式治疗。

然而,尽管分子靶向性药物在其他癌症类型中被证明有效,但大多数间皮瘤患者未能从这种新型疗法中受益。但是,新的研究表明,新型靶向药物nintedanib能够通过阻止新的间皮瘤血管的生长以切断肿瘤生长所需营养和氧气供应来抑制肿瘤组织的生长。

奥地利维也纳医科大学Viktoria Laszlo评论说:“nintedanib是间皮瘤生长和新肿瘤组织毛细血管发育的分子抑制剂,已被批准用于其他致命的胸部疾病的研究,如特发性肺纤维化和肺腺癌。此外,我们发现nintedanib能够有效地降低植入到小鼠胸腔中的人间皮瘤的生长和血管形成


原始出处:

https://www.europeanpharmaceuticalreview.com/news/75765/anticancer-nintedanib-mesothelioma/

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702941, encodeId=e6561e02941f7, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sun Jun 03 00:38:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666270, encodeId=279216662e0ab, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Wed Oct 31 02:38:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361788, encodeId=08971361e882f, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579800, encodeId=906815e980032, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=)]
    2018-06-03 aliceclz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1702941, encodeId=e6561e02941f7, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sun Jun 03 00:38:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666270, encodeId=279216662e0ab, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Wed Oct 31 02:38:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361788, encodeId=08971361e882f, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579800, encodeId=906815e980032, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=)]
    2018-10-31 lifestar
  3. [GetPortalCommentsPageByObjectIdResponse(id=1702941, encodeId=e6561e02941f7, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sun Jun 03 00:38:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666270, encodeId=279216662e0ab, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Wed Oct 31 02:38:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361788, encodeId=08971361e882f, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579800, encodeId=906815e980032, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1702941, encodeId=e6561e02941f7, content=<a href='/topic/show?id=72351e25437' target=_blank style='color:#2F92EE;'>#TED#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17254, encryptionId=72351e25437, topicName=TED)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76e230462388, createdName=aliceclz, createdTime=Sun Jun 03 00:38:00 CST 2018, time=2018-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1666270, encodeId=279216662e0ab, content=<a href='/topic/show?id=bbaf8420118' target=_blank style='color:#2F92EE;'>#胸膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84201, encryptionId=bbaf8420118, topicName=胸膜)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc026056217, createdName=lifestar, createdTime=Wed Oct 31 02:38:00 CST 2018, time=2018-10-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361788, encodeId=08971361e882f, content=<a href='/topic/show?id=131d12808f9' target=_blank style='color:#2F92EE;'>#Nintedanib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12808, encryptionId=131d12808f9, topicName=Nintedanib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579800, encodeId=906815e980032, content=<a href='/topic/show?id=6db59e28738' target=_blank style='color:#2F92EE;'>#间皮瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97287, encryptionId=6db59e28738, topicName=间皮瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d61a16562641, createdName=1249884fm92暂无昵称, createdTime=Tue May 22 02:38:00 CST 2018, time=2018-05-22, status=1, ipAttribution=)]

相关资讯

NEJM:Nintedanib对特发性肺纤维化安全有效(INPULSIS试验)?

Nintedanib (曾被称为BIBF1120)是一种靶向多种酪氨酸激酶的细胞内抑制剂,目前主要用于非小细胞肺癌的治疗(相关资讯:Lancet Oncol:nintedanib二线有效治疗非小细胞肺癌(LUME-lung 1试验)。一项II期临床试验表明,每天2次、每次150 mg nintedanib疗法可减少特发性肺纤维化患者肺功能衰退和急性加重的发生。英国、美国、日本、德国和法国

勃林格血管激酶抑制剂Ofev(nintedanib)在欧美喜获治疗系统性硬化症(SSc)的孤儿药地位

德国制药巨头勃林格殷格翰(Boehringer Ingelheim)在研药物Ofev(nintedanib,尼达尼布)近日在欧美监管方面同时传来喜讯,欧盟委员会(EC)和美国食品和药物管理局(FDA)均授予Ofev治疗系统性硬化症(systemic sclerosis,SSc)的孤儿药地位,包括系统性硬化症相关间质性肺疾病(SSc-ILD)。 系统性硬化症(SSc)俗称“硬皮病”,这是一种以局限

Lancet Oncol:标准一线化疗方案加Nintedanib治疗晚期卵巢癌效果显著

血管生成是治疗卵巢癌的靶点。Nintedanib,一种VEGF受体,血小板衍生的生长因子受体,成纤维细胞生长因子受体的口服三联血管激酶抑制剂,已经在2期试验中显示出活性。该研究nintedanib联合标准卡铂和紫杉醇化疗相结合治疗新诊断的晚期卵巢癌患者。在这项双盲3期临床试验中,患有国际妇产科联合会(FIGO)IIB-IV期卵巢癌并通过前期细胞减灭术化疗初治的患者(年龄在18岁或以上),通过术后切

ASCO 2013:一线治疗之Nintedanib对索拉非尼的头对头临床试验

Nintedanib是一个口服的酪氨酸激酶抑制剂,靶点包括VEGF、PDGF和FGF信号通路。在这个2期临床研究中,患者按照2:1的比例随机接受nintedanib或索拉非尼治疗,预期2013年年底可以获得研究结果。 Open-label, phase I/randomized, phase II trial of the triple angiokinase inhibitor, ninted

Baidu
map
Baidu
map
Baidu
map